Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells

Ecem Kaya-Sezginer, (Ankara Üniversitesi, Eczacılık Fakültesi, Biyokimya Anabilim Dalı, Ankara, Türkiye)
Ömer Faruk KIRLANGIÇ, (Ankara Üniversitesi, Sağlık Meslek Yüksekokulu, Ankara, Türkiye)
Cengiz KARAKAYA, (Gazi Üniversitesi, Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Ankara, Türkiye)
Sema ÖREN, (Sağlık Bilimleri Üniversitesi, Gülhane Sağlık Bilimleri Enstitüsü, Ar-Ge Merkezi, Ankara, Türkiye)
TUĞBA FATSA, (Sağlık Bilimleri Üniversitesi, Gülhane Sağlık Bilimleri Enstitüsü, Ar-Ge Merkezi, Ankara, Türkiye)
Taner ÖZGÜRTAŞ (Sağlık Bilimleri Üniversitesi, Gülhane Tıp Fakültesi, Tıbbi Biyokimya Anabilim Dalı, Ankara, Türkiye)
Journal of research in pharmacy (online)
1 0
Yıl: 2023 Cilt: 27 Sayı: 1 Sayfa Aralığı: 329 - 338 Metin Dili: İngilizce DOI: 10.29228/jrp.315 İndeks Tarihi: 31-05-2023

Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells

Öz:
This study investigated the apoptotic effects of a histone deacetylase (HDAC) inhibitor, sodium butyrate (NaBu) and cisplatin as monotherapy or in combination on SH-SY5Y human neuroblastoma cells. MTT and colony formation assays were performed to investigate the anti-proliferative effects of NaBu in combination with cisplatin. Analysis of SH-SY5Y cell apoptosis was performed by Annexin V-FITC/PI and DAPI staining. The gene and protein expressions were measured by RT-PCR and Western blot. The cytotoxic effect of the combined treatment was higher than single treatments, while the combination of two did not show much higher inhibition of colony formation and induction of apoptosis compared to cisplatin alone. Treatment with cisplatin upregulated the expression of Bax and Bcl-2 and combination treatment enhanced Bax gene expression and Bax/Bcl-2 ratio. NaBu alone and combined with cisplatin enhanced the expression of nuclear factor kappa B (NF-κB) protein, however cisplatin alone significantly decreased NF-κB protein levels. p53 and phosphorylated inhibitor kappa B alpha (p-IκBα) expression did not alter following any of the treatments. The combination of NaBu with cisplatin did not show any additional benefit in SH-SY5Y human neuroblastoma cells compared to cisplatin as a conventional chemotherapeutic agent, probably due to the upregulation of antiapoptotic transcription factor NF-κB.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Singh SD, Henley SJ, Ryerson AB. Surveillance for Cancer Incidence and Mortality-United States, 2012. MMWR Morb Mortal Wkly Rep. 2016; 63(55): 17-58. [CrossRef]
  • [2] de Moura Escobar SJ, Simone M, Martin N, de Oliveira Ribeiro CA, Martinez GR, Winnischofer SMB, Witting PK, Rocha MEM. Cytotoxic effects of 4'-hydroxychalcone on human neuroblastoma cells (SH-SY5Y). Toxicol In Vitro. 2019; 61: 104640. [CrossRef]
  • [3] Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17(7): 2264-2279. [CrossRef]
  • [4] Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007; 369(9579): 2106-2120. [CrossRef]
  • [5] Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011; 41(5): 345-353. [CrossRef]
  • [6] Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017; 17(4): 369-386. [CrossRef]
  • [7] De Bernardi B, Carli M, Casale F, Curciulo P, Dimontezemolo LC, Delaurentis C, Bagnulo S, Brisigotti M, Marchese N, Garaventa A, Felici L, Locurto M, Viscoli, C, Tamaro P, Rogers D, Boni L, Dini G, Bruzzi P. Standard-dose and high-dose peptichemio and cisplatin in children with disseminated poor-risk neuroblastoma: two studies by the Italian Cooperative Group for Neuroblastoma. J Clin Oncol. 1992; 10(12): 1870-1878. [CrossRef]
  • [8] Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740: 364-378. [CrossRef]
  • [9] Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011; 3(1): 1351-1371. [CrossRef]
  • [10] Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen, L, London WB, Gurney JG, Bhatia S. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol. 2014; 32(6): 527-534. [CrossRef]
  • [11] Vella S, Penna I, Longo L, Pioggia G, Garbati P, Florio T, Rossi F, Pagano A. Perhexiline maleate enhances antitumor efficacy of cisplatin in neuroblastoma by inducing over-expression of NDM29 ncRNA. Sci Rep. 2015; 5: 18144. [CrossRef]
  • [12] Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, Lynch J, Bray IM, O’Meara A, Davidoff AM, Stallings RL. MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome. Br J Cancer. 2012; 107(6): 967-976. [CrossRef]
  • [13] Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31(15): 1869-1883. [CrossRef]
  • [14] Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004; 26(4): 227-232. [CrossRef]
  • [15] Laverdiere C, Cheung NKV, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005; 45(3): 324-332. [CrossRef]
  • [16] Gilardini Montani MS, Granato M, Santoni C, Del Porto P, Merendino N, D’Orazi G, Faggioni A, Cirone M. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol (Dordr). 2017; 40(2): 167-180. [CrossRef]
  • [17] Lapinska K, Housman G, Byler S, Heerboth S, Willbanks A, Oza A, Sarkar S. The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. Anticancer Res. 2016; 36(11): 5731-5742. [CrossRef]
  • [18] Wang F, Wu H, Fan M Yu R, Zhang Y, Liu J, Zhou X, Cai Y, Huang S, Hu Z, Jin X. Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells. FASEB J. 2020; 34(3): 4266-4282. [CrossRef]
  • [19] Wang W, Fang D, Zhang H, Xue J, Wangchuk D, Du J, Jiang L. Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1. Onco Targets Ther. 2020; 13: 4691-4704. [CrossRef]
  • [20] Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature. 2017; 543(7645): 428-432. [CrossRef]
  • [21] Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Sodium butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest. BMC Mol Biol. 2010; 11: 49. [CrossRef]
  • [22] Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol. 1997; 6(3): 133-142. [CrossRef]
  • [23] Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009; 122(Pt 4): 437-441. [CrossRef]
  • [24] Xia Y, Shen S, Verma IM. NF-kappaB, an active player in human cancers. Cancer Immunol Res. 2014; 2(9): 823-830. [CrossRef]
  • [25] Korner M, Tarantino N, Pleskoff O, Lee LM, Debre P. Activation of nuclear factor kappa B in human neuroblastoma cell lines. J Neurochem. 1994; 62(5): 1716-1726. [CrossRef]
  • [26] Wu J, Harris NL, Inge TH. Nuclear factor-kappa B and apoptosis inducing factor activation by doxorubicin analog WP744 in SH-SY5Y neuroblastoma cells. J Surg Res. 2004; 122(2): 231-239. [CrossRef]
  • [27] Maruyama T, Yamamoto S, Qiu J, Ueda Y, Suzuki T, Nojima M, Shima H. Apoptosis of bladder cancer by sodium butyrate and cisplatin. J Infect Chemother. 2012; 18(3): 288-295. [CrossRef]
  • [28] Semaan J, El-Hakim S, Ibrahim JN, Safi R, Einar AA, El Boustany C. Comparative effect of sodium butyrate and sodium propionate on proliferation, cell cycle and apoptosis in human breast cancer cells MCF-7. Breast Cancer. 2020; 27(4): 696-705. [CrossRef]
  • [29] Xi Y, Jing Z, Wei W, Chun Z, Quan Q, Qing Z, Jiamin X, Shuwen H. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer. 2021; 21(1): 127. [CrossRef]
  • [30] Mrkvicova A, Chmelarova M, Peterova E, Havelek R, Baranova I, Kazimirova P, Rudolf E, Rezacova M. The effect of sodium butyrate and cisplatin on expression of EMT markers. PLoS One. 2019; 14(1): e0210889. [CrossRef]
  • [31] Chen M, Jiang W, Xiao C, Yang W, Qin Q, Mao A, Tan Q, Lian B, Wei C. Sodium Butyrate Combined with Docetaxel for the Treatment of Lung Adenocarcinoma A549 Cells by Targeting Gli1. Onco Targets Ther. 2020; 13: 8861-8875. [CrossRef]
  • [32] Kitazono M, Shinchi H, Ishigami S, Ueno S, Natsugoe S. Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells. Curr Ther Res Clin Exp. 2010; 71(3): 162-172. [CrossRef]
  • [33] Li Y, He P, Liu Y, Qi M, Dong W. Combining Sodium Butyrate With Cisplatin Increases the Apoptosis of Gastric Cancer In Vivo and In Vitro via the Mitochondrial Apoptosis Pathway. Front Pharmacol. 2021; 12: 708093. [CrossRef]
  • [34] Li W, Ma G, Deng Y, Wu Q, Wang Z, Qinghua Z. Artesunate exhibits synergistic anti-cancer effects with cisplatin on lung cancer A549 cells by inhibiting MAPK pathway. Gene. 2021; 766: 145134. [CrossRef]
  • [35] Salimi V, Shahsavari Z, Safizadeh B, Hosseini A, Khademian N, Tavakoli-Yaraki M. Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment. Lipids Health Dis. 2017; 16(1): 208. [CrossRef]
  • [36] Qin X, Xu Y, Peng S, Qian S, Zhang X, Shen S, Yang J, Ye J. Sodium butyrate opens mitochondrial permeability transition pore (MPTP) to induce a proton leak in induction of cell apoptosis. Biochem Biophys Res Commun. 2020; 527(3): 611-617. [CrossRef]
  • [37] Estaquier J, Vallette F, Vayssiere JL, Mignotte B. The mitochondrial pathways of apoptosis. Adv Exp Med Biol. 2012; 942: 157-183. [CrossRef]
  • [38] Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996; 69(2): 114-119. [CrossRef]
  • [39] Chopin V, Toillon RA, Jouy N, Le Bourhis X. Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol. 2002; 135(1): 79-86. [CrossRef]
  • [40] Kuefer R, Hofer MD, Altug V, Zorn C, Genze F, Kunzi-Rapp K, Hautmann RE, Gschwend JE. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004; 90(2): 535-541. [CrossRef]
  • [41] Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T, Tamura Y, Satone A, Ide W, Hashimoto I, Kamada H. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2001; 18(2): 109-114. [CrossRef]
  • [42] Mu D, Gao Z, Guo H, Zhou G, Sun B. Sodium butyrate induces growth inhibition and apoptosis in human prostate cancer DU145 cells by up-regulation of the expression of annexin A1. PLoS One. 2013; 8(9): e74922. [CrossRef]
  • [43] Perego S, Sansoni V, Banfi G, Lombardi G. Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFalpha-induced low-grade inflammation. Int J Immunopathol Pharmacol. 2018; 32: 394632017752240. [CrossRef]
  • [44] Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, Jones DR. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway. J Biol Chem. 2003; 278(21): 18980-18989. [CrossRef]
  • [45] Al-Bahlani S, Burney IA, Al-Dhahli B, Al-Kharusi S, Al-Karousi F, Al-Kalbani A, Ahmed I. Boswellic acid sensitizes gastric cancer cells to Cisplatin-induced apoptosis via p53-mediated pathway. BMC Pharmacol Toxicol. 2020; 21(1): 64. [CrossRef]
APA Kaya-Sezginer E, KIRLANGIÇ Ö, KARAKAYA C, Ören S, FATSA T, Ozgurtas T (2023). Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. , 329 - 338. 10.29228/jrp.315
Chicago Kaya-Sezginer Ecem,KIRLANGIÇ Ömer Faruk,KARAKAYA Cengiz,Ören Sema,FATSA TUĞBA,Ozgurtas Taner Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. (2023): 329 - 338. 10.29228/jrp.315
MLA Kaya-Sezginer Ecem,KIRLANGIÇ Ömer Faruk,KARAKAYA Cengiz,Ören Sema,FATSA TUĞBA,Ozgurtas Taner Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. , 2023, ss.329 - 338. 10.29228/jrp.315
AMA Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. . 2023; 329 - 338. 10.29228/jrp.315
Vancouver Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. . 2023; 329 - 338. 10.29228/jrp.315
IEEE Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T "Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells." , ss.329 - 338, 2023. 10.29228/jrp.315
ISNAD Kaya-Sezginer, Ecem vd. "Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells". (2023), 329-338. https://doi.org/10.29228/jrp.315
APA Kaya-Sezginer E, KIRLANGIÇ Ö, KARAKAYA C, Ören S, FATSA T, Ozgurtas T (2023). Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. Journal of research in pharmacy (online), 27(1), 329 - 338. 10.29228/jrp.315
Chicago Kaya-Sezginer Ecem,KIRLANGIÇ Ömer Faruk,KARAKAYA Cengiz,Ören Sema,FATSA TUĞBA,Ozgurtas Taner Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. Journal of research in pharmacy (online) 27, no.1 (2023): 329 - 338. 10.29228/jrp.315
MLA Kaya-Sezginer Ecem,KIRLANGIÇ Ömer Faruk,KARAKAYA Cengiz,Ören Sema,FATSA TUĞBA,Ozgurtas Taner Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. Journal of research in pharmacy (online), vol.27, no.1, 2023, ss.329 - 338. 10.29228/jrp.315
AMA Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. Journal of research in pharmacy (online). 2023; 27(1): 329 - 338. 10.29228/jrp.315
Vancouver Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells. Journal of research in pharmacy (online). 2023; 27(1): 329 - 338. 10.29228/jrp.315
IEEE Kaya-Sezginer E,KIRLANGIÇ Ö,KARAKAYA C,Ören S,FATSA T,Ozgurtas T "Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells." Journal of research in pharmacy (online), 27, ss.329 - 338, 2023. 10.29228/jrp.315
ISNAD Kaya-Sezginer, Ecem vd. "Apoptosis inducing effect of sodium butyrate and cisplatin alone or in combination on SH-SY5Y human neuroblastoma cells". Journal of research in pharmacy (online) 27/1 (2023), 329-338. https://doi.org/10.29228/jrp.315
Sayfa Oluşturulma Tarihi
24-04-2024 7:37

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları